Advent France Biotechnology, Invivo invest €4.25m in Arthex

Following the deal, AFB chair and managing partner Alain Huriez will join Arthex's board of directors, alongside Invivo managing partners Luis Pareras and Albert Ferrer.

The company intends to use this fresh injection of capital to advance the development of its myotonic dystrophy therapy, with its first-in-human trial ready by 2022.

This round brings the total funds raised by Arthex to €6.95m.

Previous funding
Arthex raised an initial seed round from Invivo in December 2019 and a second seed round from and CDTI-Innvierte in June 2020, for a total of €2.7m.

Company
Founded in 2019 and headquartered in Valencia, Arthex develops RNA therapies for type 1 myotonic dystrophy, an orphan neuromuscular disease with genetic origin, for which there is currently no cure.

People
Arthex Biotech - Rubén Artero, Beatriz Llamusí (co-founders).
Advent France Biotechnology – Alain Huriez (chair, managing partner).
Invivo Ventures – Luis Pareras, Albert Ferrer (managing partners).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Southern Europe
• Healthcare
• Technology
• Venture
• Spain